From: Extracellular Vesicles for Drug Delivery in Cancer Treatment
Subtype | Size | Markers | Biogenesis/release | Refs |
---|---|---|---|---|
Exosomes | ||||
Exo-S | 50–70 nm | ESCRT complex proteins, CD9, CD63, CD81 | Exo-S mainly contains proteins that associated with endosomes, multivesicular bodies, exosomes, and phagocytic vesicles. EXO-S is most likely a classical exosome | [9] |
Exo-L | 90–120 nm | Exo-L contains proteins that associated with composition of plasma membrane, cell–cell contacts or junctions, late endosomes, and trans-Golgi network. Exo-L may represent non-classical exosomes or extracellular vesicles from different subcellular origins | ||
Microvesicles (Ectosomes) | 100 –1000 nm | Annexin A1, ARF6 | Outward budding of the plasma membrane, scission/pinching off from membrane protrusions | [6] |
Apoptotic bodies | 1000—5000 nm | Phosphatidylserine | Released from apoptotic cells upon activation of apoptosis- related transduction pathways | [5] |
Exomere | < 50 nm | Unknow | The biogenesis of exomeres may involve subcellular organelles or activities related to cellular metabolism, including organelles such as the endoplasmic reticulum and Golgi apparatus, as well as metabolic pathways within the cell | [9] |
Supermeres | Unknown | Unknown | Unknown | [10] |
Exophers | 1,000–10,000 nm | Phosphatidylserine, LC3, Tom20 | Unknown | [3] |
Retroviral- like particles | Not determined | Gag- like proteins (Arc1, Arc2) | Unknown | [4] |